FDA approves Apidra for controlling glycemic levels in young diabetes patients
BRIDGEWATER, N.J. The Food and Drug Administration has approved Apidra, a drug for improving glycemic control in diabetic children aged 4 and older, manufacturer Sanofi-Aventis said Wednesday.
The FDA’s approval is based on a 26-week, phase 3, open-label and active control study of Apidra in comparison with insulin lispro in 572 children with Type 1 diabetes.
“Sanofi-Aventis is committed to providing children with diabetes, as well as their families and healthcare providers, with safe and effective treatment options to help address the challenges associated with the condition and to help decrease the long-term risk for devastating complications of diabetes,” vice president of Sanofi-Aventis U.S.’s Metabolism Medical Unit Michelle Baron said.
Apidra is known generically as insulin glulisine (rDNA origin).
Walgreens announces promotions of several execs
DEERFIELD, Ill. Seven Walgreens executives received promotions Wednesday.
Carlo Baldan, a category manager for the sleep, pain and incontinence categories, was promoted to divisional merchandising manager for personal care in the retail pharmacy chain’s beauty and fashion division.
Robert Tompkins, the divisional merchandising manager for OTC drugs, was promoted to general merchandising manager of the health and wellness purchasing group, succeeding Chong Bang, who is now vice president of customer-centric retailing. Bob Cinq-Mars will replace Tompkins as divisional merchandise manager for OTC categories including medications for pain, sleep, incontinence, nutrition, diet and smoking cessation.
Robert Bobber, the divisional merchandise manager for consumables, will be in charge of OTC categories that Cinq-Mars previously managed. Robin Randolph, divisional merchandise manager for electronics, will take over for Bobber while maintaining her current position.
Scott Minger, associate category manager for vitamins, has been promoted to category manager for vitamins.
Lannett Co. announces patent approval for generic pain drugs
PHILADELPHIA Generic drug maker Lannett Company announced earlier this month that the United States Patent and Trademark Office granted a patent to subsidiary Cody Laboratories for a method for preparing hydromorphone and hydrocodone.
“Our patented method for preparing hydromorphone and hydrocodone will greatly enhance our ability to manufacture these products quickly and efficiently,” Lannett president and chief executive Arthur Bedrosian said. “Importantly, with minimal incremental investment, the faster manufacturing time appreciably expands our manufacturing capacity, allowing us to maximize our production assets.”
Hydromorphone and hydrocodone are opiate-derived drugs used for treating pain.